• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Change Healthcare Inc. Reports Second Quarter Fiscal 2022 Financial Results

    11/3/21 12:39:00 PM ET
    $CHNG
    Managed Health Care
    Health Care
    Get the next $CHNG alert in real time by email

    Change Healthcare Inc. (NASDAQ:CHNG) (the "Company" or "Change Healthcare"), a leading healthcare technology company, today reported financial results for the second quarter of fiscal year 2022 ended September 30, 2021.

    "Our results this quarter continue to demonstrate solid execution of our growth strategy and the underlying strength and momentum in our business," said Neil de Crescenzo, president and chief executive officer. "We continue to create value for our payer, provider and consumer customers by delivering innovative and transformative solutions. Along with our customers, we remained focused on lowering cost, enhancing access, and improving outcomes for the benefit of everyone in the healthcare system."

    Fiscal 2022 Second Quarter Highlights:

    Financial Summary

    • Total revenue of $826.8 million, including solutions revenue of $774.2 million
    • Net loss of $36.4 million, resulting in net loss of $0.11 per diluted share
    • Adjusted net income of $114.3 million, resulting in adjusted net income of $0.35 per diluted share
    • Adjusted EBITDA of $246.5 million

    Recent Business Highlights

    • Introduced Change Healthcare Stratus Imaging PACS, our new, comprehensive cloud-native solution, which is now in production with standalone radiology groups, with contracts to deploy in hospital-affiliated practices in 2022.
    • Added 118 new products to our Change Healthcare Marketplace in the second quarter, which now offers 198 products representing API, software, and hardware products from all parts of our portfolio.
    • Continued to establish new data solutions partnerships with major academic medical research centers, bringing the total to more than 75 partnerships developed to improve health equity through our Data Science as a Service offering and other solutions.
    • Continued momentum with our electronic prior authorization offering, which uses AI and predictive analytics to automate the prior authorization process and drive transparency between healthcare constituents to help the industry deliver the right care, in the right place, at the right time in a transparent manner.

    Impact of McKesson Exit on Comparability of Results

    On March 10, 2020, Change Healthcare Inc. acquired the interest in Change Healthcare LLC ("the Joint Venture") previously held by McKesson. The transaction resulted in Change Healthcare Inc. acquiring control of the Joint Venture, which was accounted for as a business combination resulting in fair value adjustments to various assets and liabilities, including deferred revenue, goodwill, and intangible assets.

    Financial Results for Second Quarter of Fiscal 2022

    • Solutions revenue was $774.2 million, compared to $705.9 million for second quarter of fiscal 2021. Solutions revenue includes the impact of fair value adjustments to deferred revenue resulting from the McKesson exit, which reduced revenue recognized by $3.3 million and $38.9 million in the second quarter of fiscal 2022 and 2021, respectively. Total revenue, which includes postage revenue, was $826.8 million compared to $755.9 million in the same period of the prior year. Solutions revenue for the current period reflects the negative $6.0 million impact during the quarter from the Capacity Management divestiture which closed in fiscal year 2021. Solutions revenue in the current period was positively impacted by volume recovery and incremental revenue from COVID-19 vaccines and new sales.
    • Net loss was $36.4 million, resulting in net loss of $0.11 per diluted share, compared with net loss of $42.6 million and $0.13 per diluted share, respectively, for the second quarter of fiscal 2021.
    • Adjusted net income was $114.3 million, resulting in adjusted net income of $0.35 per diluted share, compared with adjusted net income of $103.5 million and $0.32 per diluted share, respectively, for the second quarter of fiscal 2021. Net loss per diluted share and adjusted net income per diluted share for the current period is based on 324 million shares compared to 321 million shares in the prior year period.
    • Adjusted EBITDA was $246.5 million, compared with $231.8 million for the second quarter of fiscal 2021. The results in the current quarter reflect the aforementioned revenue growth, partially offset by investments to support business initiatives.

    Cash Flow and Balance Sheet Highlights

    Net cash provided by operating activities was $261.4 million and free cash flow was $134.5 million, in each case, for the six months ended September 30, 2021. For the six months ended September 30, 2020, net cash provided by operating activities and free cash flow was $296.6 million and $170.1 million, respectively.

    Net cash provided by operating activities and free cash flow each are affected by pass-thru funds we receive from certain pharmaceutical industry participants in advance of our obligation to remit these funds to participating retail pharmacies. Such pass-thru funds on hand increased by $4.4 million in the six months ended September 30, 2021, increasing free cash flow for the period by that amount, and decreased by $1.4 million for the six months ended September 30, 2020.

    The Company ended the quarter with approximately $80.4 million of cash and cash equivalents, and approximately $4,662.4 million of total debt. During the second quarter, the Company repaid $100.0 million on its Term Loan Facility, and repaid an additional $60.0 million subsequent to the end of the quarter.

    Update on Proposed Merger with OptumInsight

    On January 5, 2021, OptumInsight, a diversified health services company and part of UnitedHealth Group, and Change Healthcare agreed to combine (the "Merger"). Under the terms of the merger agreement, UnitedHealth Group, through a wholly-owned subsidiary, will acquire all of the outstanding shares of Change Healthcare common stock for $25.75 per share in cash. The Boards of Directors of both UnitedHealth Group and Change Healthcare have unanimously approved the terms of the Merger. At a special meeting held April 13, 2021, Change Healthcare stockholders voted to approve the Merger. Of the approximately 222 million shares voted, 99.9% voted in favor of the adoption of the merger agreement. The closing of the Merger is subject to applicable regulatory approval and other customary closing conditions.

    As previously disclosed, on March 24, 2021, the Company and UnitedHealth Group each received a request for additional information and documentary materials (collectively, the "Second Request") from the Department of Justice ("DOJ") in connection with the DOJ's review of the Merger, and on August 7, 2021, the parties entered into a timing agreement (the "Timing Agreement") with the DOJ pursuant to which they agreed not to consummate the Merger before 120 days following the date on which both parties certified substantial compliance with the Second Request.

    Both the Company and UnitedHealth Group have now certified substantial compliance with the Second Request. On November 1, 2021, the Company and UnitedHealth Group entered into an amendment to the Timing Agreement with the DOJ pursuant to which they agreed not to consummate the Merger before 12:01 a.m. Eastern Time on February 22, 2022 (subject to extension in certain limited circumstances relating to the potential unavailability of certain requested data), unless they have received written notice from the DOJ prior to such date that the DOJ has closed its investigation. The parties have been working cooperatively with the DOJ and will continue to do so.

    Guidance

    Due to the proposed transaction with OptumInsight, we will no longer be providing financial guidance.

    Webcast Information

    Change Healthcare will host a conference call on Thursday, November 4, 2021, at 8:00 a.m. ET. Due to the previously announced transaction with OptumInsight, the Company will not be taking questions during the conference call.

    Investors and other interested parties are invited to listen to the conference call via the Company's website at https://ir.changehealthcare.com/. The webcast will be available for on-demand listening at the aforementioned URL until November 4, 2022.

    About Change Healthcare

    Change Healthcare (NASDAQ:CHNG) is a leading healthcare technology company, focused on insights, innovation, and accelerating the transformation of the U.S. healthcare system through the power of the Change Healthcare platform. We provide data and analytics-driven solutions to improve clinical, financial, administrative, and patient engagement outcomes in the U.S. healthcare system. Learn more at changehealthcare.com.

    CHNG-IR

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to the financial condition, results of operations and businesses of Change Healthcare. Some of these statements can be identified by terms and phrases such as "anticipate," "believe," "intend," "estimate," "expect," "continue," "could," "should," "may," "plan," "project," "predict" and similar expressions. Change Healthcare cautions readers of this press release that such "forward looking statements," including without limitation, those relating to the timing of the proposed merger and Change Healthcare's future business prospects, revenue, working capital, liquidity, capital needs, interest costs and income, wherever they occur in this press release or in other statements attributable to Change Healthcare, are necessarily estimates reflecting the judgment of Change Healthcare's senior management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the "forward looking statements."

    Factors that could cause Change Healthcare's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to, the inability to complete the proposed merger due to the failure to satisfy conditions to completion of the proposed merger, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; risks related to disruption of management's attention from Change Healthcare's ongoing business operations due to the transaction; the effect of the announcement of the proposed merger on Change Healthcare's relationships with its customers, operating results and business generally; the risk that the proposed merger will not be consummated in a timely manner; exceeding the expected costs of the merger; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; macroeconomic and industry trends and adverse developments in the debt, consumer credit and financial services markets; uncertainty and risks related to the impact of the COVID-19 pandemic (including the rise of COVID-19 variant strains such as the Delta variant) on the national and global economy, Change Healthcare's business, suppliers, customers, and employees; Change Healthcare's ability to retain or renew existing customers and attract new customers; Change Healthcare's ability to connect a large number of payers and providers; Change Healthcare's ability to provide competitive services and prices while maintaining its margins; further consolidation in end-customer markets; Change Healthcare's ability to effectively manage costs; Change Healthcare's ability to effectively develop and maintain relationships with channel partners; Change Healthcare's ability to timely develop new services and the market's willingness to adopt new services; Change Healthcare's ability to deliver services timely without interruption; a decline in transaction volume in the U.S. healthcare industry; Change Healthcare's ability to maintain access to its data sources; Change Healthcare's ability to maintain the security and integrity of its data; Change Healthcare's ability to retain and recruit key management personnel and other talent (including while the proposed merger is pending and in light of Change Healthcare's recently imposed COVID-19 vaccine mandate); Change Healthcare's ability to manage and expand its operations and keep up with rapidly changing technologies; the ability of outside service providers and key vendors to fulfill their obligations to Change Healthcare; risks related to international operations; Change Healthcare's ability to protect and enforce its intellectual property, trade secrets and other forms of unpatented intellectual property; Change Healthcare's ability to defend its intellectual property from infringement claims by third parties; government regulation and changes in the regulatory environment; changes in local, state, federal and international laws and regulations, including related to taxation; economic and political instability in the U.S. and international markets where Change Healthcare operates; litigation or regulatory proceedings; losses against which Change Healthcare does not insure; Change Healthcare's ability to make acquisitions and integrate the operations of acquired businesses; Change Healthcare's ability to make timely payments of principal and interest on its indebtedness; Change Healthcare's ability to satisfy covenants in the agreements governing its indebtedness; Change Healthcare's ability to maintain liquidity; our adoption of new, or amendments to existing, accounting standards, and other risks. For a more detailed discussion of these factors, see the information under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Change Healthcare's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on May 27, 2021 as such factors may be updated from time to time in our periodic filings with the SEC.

    Change Healthcare's forward-looking statements speak only as of the date of this press release or as of the date they are made. Change Healthcare disclaims any intent or obligation to update any "forward-looking statement" made in this press release to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time.

    Non-GAAP Financial Measures

    In the Company's earnings releases, prepared remarks, conference calls, slide presentations and webcasts, there may be use or discussion of non-GAAP financial measures. We believe such measures provide supplemental information to investors with regards to our operating performance and assist investors' ability to compare our financial results to those of other companies in the same industry. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between the comparable GAAP financial measure and each non-GAAP financial measure are included in this press release after the consolidated financial statements. These non-GAAP financial measures are calculated and presented on the basis of methodologies other than in accordance with GAAP. These non-GAAP financial measures should be considered only as supplemental to, and not as superior to, financial measures prepared in accordance with GAAP and may be defined and calculated differently by others in the same industry.

     

    Consolidated Statements of Operations

    (unaudited and amounts in thousands, except share and per share amounts)

     

     

     

     

     

     

     

     

     

     

    Three Months Ended September 30,

     

     

    2021

     

    2020

    Revenue:

     

     

     

     

     

     

    Solutions revenue

     

    $

    774,214

     

    $

    705,913

    Postage revenue

     

     

    52,550

     

     

    50,023

    Total revenue

     

     

    826,764

     

     

    755,936

    Operating expenses:

     

     

     

     

     

     

    Cost of operations (exclusive of depreciation and amortization below)

     

     

    346,632

     

     

    326,653

    Research and development

     

     

    67,070

     

     

    54,052

    Sales, marketing, general and administrative

     

     

    183,041

     

     

    171,606

    Customer postage

     

     

    52,550

     

     

    50,023

    Depreciation and amortization

     

     

    163,469

     

     

    146,869

    Accretion and changes in estimate with related parties, net

     

     

    2,870

     

     

    3,564

    Gain on sale of businesses

     

     

    —

     

     

    (176)

    Total operating expenses

     

     

    815,632

     

     

    752,591

    Operating income (loss)

     

     

    11,132

     

     

    3,345

    Non-operating (income) and expense

     

     

     

     

     

     

    Interest expense, net

     

     

    59,466

     

     

    61,627

    Loss on extinguishment of debt

     

     

    2,232

     

     

    1,489

    Other, net

     

     

    2,587

     

     

    (3,761)

    Total non-operating (income) and expense

     

     

    64,285

     

     

    59,355

    Income (loss) before income tax provision (benefit)

     

     

    (53,153)

     

     

    (56,010)

    Income tax provision (benefit)

     

     

    (16,749)

     

     

    (13,388)

    Net income (loss)

     

    $

    (36,404)

     

    $

    (42,622)

     

     

     

     

     

     

     

    Net income (loss) per common share:

     

     

     

     

     

     

    Basic and diluted

     

    $

    (0.11)

     

    $

    (0.13)

    Weighted average common shares outstanding:

     

     

     

     

     

     

    Basic and diluted

     

     

    324,060,460

     

     

    320,638,116

     
     

    Consolidated Statements of Operations

    (unaudited and amounts in thousands, except share and per share amounts)

     

     

     

     

     

     

     

     

     

    Six Months Ended September 30,

     

     

    2021

     

    2020

    Revenue:

     

     

     

     

     

     

    Solutions revenue

     

    $

    1,590,862

     

    $

    1,354,325

    Postage revenue

     

     

    103,758

     

     

    95,795

    Total revenue

     

     

    1,694,620

     

     

    1,450,120

    Operating expenses:

     

     

     

     

     

     

    Cost of operations (exclusive of depreciation and amortization below)

     

     

    698,695

     

     

    645,195

    Research and development

     

     

    138,310

     

     

    109,787

    Sales, marketing, general and administrative

     

     

    360,997

     

     

    337,080

    Customer postage

     

     

    103,758

     

     

    95,795

    Depreciation and amortization

     

     

    331,681

     

     

    285,409

    Accretion and changes in estimate with related parties, net

     

     

    5,907

     

     

    9,459

    Gain on sale of businesses

     

     

    —

     

     

    (28,270)

    Total operating expenses

     

     

    1,639,348

     

     

    1,454,455

    Operating income (loss)

     

     

    55,272

     

     

    (4,335)

    Non-operating (income) and expense

     

     

     

     

     

     

    Interest expense, net

     

     

    118,852

     

     

    124,294

    Loss on extinguishment of debt

     

     

    2,232

     

     

    1,489

    Other, net

     

     

    (605)

     

     

    (1,953)

    Total non-operating (income) and expense

     

     

    120,479

     

     

    123,830

    Income (loss) before income tax provision (benefit)

     

     

    (65,207)

     

     

    (128,165)

    Income tax provision (benefit)

     

     

    (25,198)

     

     

    (26,849)

    Net income (loss)

     

    $

    (40,009)

     

    $

    (101,316)

     

     

     

     

     

     

     

    Net income (loss) per common share:

     

     

     

     

     

     

    Basic and diluted

     

    $

    (0.12)

     

    $

    (0.32)

    Weighted average common shares outstanding:

     

     

     

     

     

     

    Basic and diluted

     

     

    323,309,280

     

     

    320,347,128

     
     

    Consolidated Balance Sheets

    (unaudited and amounts in thousands, except share and per share amounts)

     

     

     

     

     

     

     

     

     

    September 30, 2021

     

    March 31, 2021

    Assets

     

     

     

     

     

     

    Current assets:

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    80,414

     

    $

    113,101

    Accounts receivable, net

     

     

    704,595

     

     

    732,614

    Contract assets, net

     

     

    128,010

     

     

    132,856

    Prepaid expenses and other current assets

     

     

    149,176

     

     

    140,258

    Total current assets

     

     

    1,062,195

     

     

    1,118,829

    Property and equipment, net

     

     

    150,579

     

     

    174,370

    Operating lease right-of-use assets, net

     

     

    80,562

     

     

    93,412

    Goodwill

     

     

    4,110,823

     

     

    4,108,792

    Intangible assets, net

     

     

    3,942,164

     

     

    4,187,072

    Other noncurrent assets, net

     

     

    503,405

     

     

    430,141

    Total assets

     

    $

    9,849,728

     

    $

    10,112,616

    Liabilities

     

     

     

     

     

     

    Current liabilities:

     

     

     

     

     

     

    Accounts payable

     

    $

    64,756

     

    $

    57,449

    Accrued expenses

     

     

    463,510

     

     

    484,293

    Deferred revenue

     

     

    377,270

     

     

    436,666

    Due to related parties, net

     

     

    11,392

     

     

    10,766

    Current portion of long-term debt

     

     

    19,152

     

     

    27,339

    Current portion of operating lease liabilities

     

     

    28,948

     

     

    30,608

    Total current liabilities

     

     

    965,028

     

     

    1,047,121

    Long-term debt, excluding current portion

     

     

    4,643,245

     

     

    4,734,775

    Long-term operating lease liabilities

     

     

    62,001

     

     

    75,396

    Deferred income tax liabilities

     

     

    578,584

     

     

    605,291

    Tax receivable agreement obligations to related parties

     

     

    97,606

     

     

    103,151

    Tax receivable agreement obligations

     

     

    196,687

     

     

    229,082

    Other long-term liabilities

     

     

    62,411

     

     

    65,572

    Total liabilities

     

     

    6,605,562

     

     

    6,860,388

    Commitments and contingencies

     

     

     

     

     

     

    Stockholders' Equity

     

     

     

     

     

     

    Common Stock (par value, $0.001), 9,000,000,000 and 9,000,000,000 shares authorized and 311,311,208 and 306,796,076 shares issued and outstanding at September 30, 2021 and March 31, 2021, respectively

     

     

    311

     

     

    307

    Preferred stock (par value, $0.001), 900,000,000 shares authorized and no shares issued and outstanding at both September 30, 2021 and March 31, 2021

     

     

    —

     

     

    —

    Additional paid-in capital

     

     

    4,313,759

     

     

    4,283,391

    Accumulated other comprehensive income (loss)

     

     

    12,796

     

     

    11,221

    Accumulated deficit

     

     

    (1,082,700)

     

     

    (1,042,691)

    Total stockholders' equity

     

     

    3,244,166

     

     

    3,252,228

    Total liabilities and stockholders' equity

     

    $

    9,849,728

     

    $

    10,112,616

     
     

    Consolidated Statements of Cash Flows

    (unaudited and amounts in thousands)

     

     

     

     

     

     

     

     

     

    Six Months Ended September 30,

     

     

    2021

     

    2020

    Cash flows from operating activities:

     

     

     

     

     

     

    Net income (loss)

     

    $

    (40,009)

     

    $

    (101,316)

    Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

     

     

     

     

     

     

    Depreciation and amortization

     

     

    331,681

     

     

    285,409

    Amortization of capitalized software developed for sale

     

     

    1,576

     

     

    89

    Accretion and changes in estimate, net

     

     

    9,087

     

     

    11,188

    Equity compensation

     

     

    49,911

     

     

    23,914

    Deferred income tax expense (benefit)

     

     

    (26,560)

     

     

    (28,590)

    Amortization of debt discount and issuance costs

     

     

    15,820

     

     

    16,551

    Loss on extinguishment of debt

     

     

    2,232

     

     

    1,489

    Non-cash lease expense

     

     

    13,958

     

     

    14,629

    Gain on sale of businesses

     

     

    —

     

     

    (28,270)

    Other, net

     

     

    7,405

     

     

    4,530

    Changes in operating assets and liabilities:

     

     

     

     

     

     

    Accounts receivable, net

     

     

    27,860

     

     

    114,052

    Contract assets, net

     

     

    4,154

     

     

    (3,786)

    Prepaid expenses and other assets

     

     

    (37,833)

     

     

    (48,382)

    Accounts payable

     

     

    7,644

     

     

    (28,666)

    Accrued expenses and other liabilities

     

     

    (43,743)

     

     

    27,687

    Deferred revenue

     

     

    (61,832)

     

     

    36,029

    Net cash provided by (used in) operating activities

     

     

    261,351

     

     

    296,557

    Cash flows from investing activities:

     

     

     

     

     

     

    Capitalized expenditures

     

     

    (126,828)

     

     

    (126,432)

    Acquisitions, net of cash acquired

     

     

    —

     

     

    (439,483)

    Proceeds from sale of businesses

     

     

    —

     

     

    54,369

    Other, net

     

     

    (1,000)

     

     

    1,100

    Net cash provided by (used in) investing activities

     

     

    (127,828)

     

     

    (510,446)

    Cash flows from financing activities:

     

     

     

     

     

     

    Payments on Term Loan Facility

     

     

    (100,000)

     

     

    (50,000)

    Payments under tax receivable agreements

     

     

    (21,537)

     

     

    (20,691)

    Receipts (payments) on derivative instruments

     

     

    (14,810)

     

     

    (14,810)

    Employee tax withholding on vesting of equity compensation awards

     

     

    (18,681)

     

     

    (3,131)

    Payments on deferred financing obligations

     

     

    (8,981)

     

     

    (6,547)

    Payment of senior amortizing notes

     

     

    (8,048)

     

     

    (7,680)

    Proceeds from exercise of equity awards

     

     

    5,985

     

     

    2,584

    Payments on Revolving Facility

     

     

    —

     

     

    (250,000)

    Proceeds from issuance of Senior Notes

     

     

    —

     

     

    325,000

    Other, net

     

     

    (253)

     

     

    (6,454)

    Net cash provided by (used in) financing activities

     

     

    (166,325)

     

     

    (31,729)

    Effect of exchange rate changes on cash and cash equivalents

     

     

    115

     

     

    2,690

    Net increase (decrease) in cash and cash equivalents

     

     

    (32,687)

     

     

    (242,928)

    Cash and cash equivalents at beginning of period

     

     

    113,101

     

     

    410,405

    Cash and cash equivalents at end of period

     

    $

    80,414

     

    $

    167,477

     
     

    Reconciliation of Net Income (Loss) to Adjusted EBITDA

    (unaudited and amounts in thousands)

     

     

     

     

     

     

     

     

     

    Three Months Ended September 30,

     

     

    2021

     

    2020

    Net income (loss)

     

    $

    (36,404)

     

    $

    (42,622)

    Income tax provision (benefit)

     

     

    (16,749)

     

     

    (13,388)

    Income (loss) before income tax provision (benefit)

     

     

    (53,153)

     

     

    (56,010)

    Amortization of capitalized software developed for sale

     

     

    859

     

     

    12

    Depreciation and amortization

     

     

    163,469

     

     

    146,869

    Interest expense, net

     

     

    59,466

     

     

    61,627

    Equity compensation

     

     

    23,745

     

     

    14,331

    Acquisition accounting adjustments

     

     

    (1,653)

     

     

    34,686

    Acquisition and divestiture-related costs

     

     

    13,765

     

     

    2,337

    Integration and related costs

     

     

    5,933

     

     

    7,536

    Strategic initiatives, duplicative and transition costs

     

     

    14,644

     

     

    3,765

    Severance costs

     

     

    7,303

     

     

    3,172

    Accretion and changes in estimate, net

     

     

    4,355

     

     

    5,293

    Impairment of long-lived assets and other

     

     

    81

     

     

    7,447

    Loss on extinguishment of debt

     

     

    2,232

     

     

    1,489

    Gain on sale of business

     

     

    —

     

     

    (176)

    Contingent consideration

     

     

    —

     

     

    (550)

    Other non-routine, net

     

     

    5,416

     

     

    13

    Adjusted EBITDA

     

    $

    246,462

     

     

    231,841

     
     

    Reconciliation of Net Income (Loss) to Adjusted EBITDA

    (unaudited and amounts in thousands)

     

     

     

     

     

     

     

     

     

    Six Months Ended September 30,

     

     

    2021

     

    2020

    Net income (loss)

     

    $

    (40,009)

     

    $

    (101,316)

    Income tax provision (benefit)

     

     

    (25,198)

     

     

    (26,849)

    Income (loss) before income tax provision (benefit)

     

     

    (65,207)

     

     

    (128,165)

    Amortization of capitalized software developed for sale

     

     

    1,576

     

     

    89

    Depreciation and amortization

     

     

    331,681

     

     

    285,409

    Interest expense, net

     

     

    118,852

     

     

    124,294

    Equity compensation

     

     

    49,911

     

     

    23,914

    Acquisition accounting adjustments

     

     

    (2,212)

     

     

    83,225

    Acquisition and divestiture-related costs

     

     

    20,159

     

     

    7,458

    Integration and related costs

     

     

    17,301

     

     

    17,894

    Strategic initiatives, duplicative and transition costs

     

     

    24,572

     

     

    8,845

    Severance costs

     

     

    12,023

     

     

    7,876

    Accretion and changes in estimate, net

     

     

    9,087

     

     

    11,188

    Impairment of long-lived assets and other

     

     

    1,692

     

     

    13,760

    Loss on extinguishment of debt

     

     

    2,232

     

     

    1,489

    Gain on sale of business

     

     

    —

     

     

    (28,270)

    Contingent consideration

     

     

    —

     

     

    (3,000)

    Other non-routine, net

     

     

    7,523

     

     

    2,690

    Adjusted EBITDA

     

    $

    529,190

     

     

    428,696

     
     

    Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss)

    (unaudited and amounts in thousands, except share and per share amounts)

     

     

     

     

     

     

     

     

     

    Three Months Ended September 30,

     

     

    2021

     

    2020

    Net income (loss)

     

    $

    (36,404)

     

    $

    (42,622)

    Amortization expense resulting from acquisition method adjustments

     

     

    124,465

     

     

    115,873

    EBITDA adjustments

     

     

    75,821

     

     

    79,343

    Tax effect of EBITDA adjustments and amortization expense

     

     

    (49,590)

     

     

    (49,107)

    Adjusted net income (loss)

     

    $

    114,292

     

     

    103,487

     

     

     

     

     

     

     

    Adjusted net income (loss) per diluted share

     

    $

    0.35

     

     

    0.32

     

     

     

     

     

     

     

     

     

    Six Months Ended September 30,

     

     

    2021

     

    2020

    Net income (loss)

     

    $

    (40,009)

     

    $

    (101,316)

    Amortization expense resulting from acquisition method adjustments

     

     

    248,779

     

     

    228,898

    EBITDA adjustments

     

     

    142,288

     

     

    147,069

    Tax effect of EBITDA adjustments and amortization expense

     

     

    (103,811)

     

     

    (89,966)

    Adjusted net income (loss)

     

    $

    247,247

     

     

    184,685

     

     

     

     

     

     

     

    Adjusted net income (loss) per diluted share

     

    $

    0.76

     

     

    0.58

     
     

    Segment Results

    (unaudited and amounts in thousands)

     

     

     

     

     

     

     

     

     

    Three Months Ended September 30,

     

     

    2021

     

    2020

    Segment revenue

     

     

     

     

     

     

    Software and Analytics

     

    $

    363,423

     

     

    354,860

    Network Solutions

     

     

    215,600

     

     

    184,095

    Technology-Enabled Services

     

     

    231,928

     

     

    231,817

    Postage and Eliminations (1)

     

     

    19,091

     

     

    24,073

    Purchase Accounting Adjustment (2)

     

     

    (3,278)

     

     

    (38,909)

    Net revenue

     

    $

    826,764

     

     

    755,936

     

     

     

     

     

     

     

    Segment adjusted EBITDA

     

     

     

     

     

     

    Software and Analytics

     

    $

    112,318

     

     

    117,393

    Network Solutions

     

     

    112,986

     

     

    94,508

    Technology-Enabled Services

     

     

    21,158

     

     

    19,940

    Postage and Eliminations

     

     

    —

     

     

    —

    Total adjusted EBITDA

     

    $

    246,462

     

     

    231,841

     

     

     

     

     

     

     

     

     

    Six Months Ended September 30,

     

     

    2021

     

    2020

    Segment revenue

     

     

     

     

     

     

    Software and Analytics

     

    $

    783,740

     

     

    746,449

    Network Solutions

     

     

    425,061

     

     

    326,921

    Technology-Enabled Services

     

     

    457,450

     

     

    419,523

    Postage and Eliminations (1)

     

     

    36,109

     

     

    51,136

    Purchase Accounting Adjustment (2)

     

     

    (7,740)

     

     

    (93,909)

    Net revenue

     

    $

    1,694,620

     

     

    1,450,120

     

     

     

     

     

     

     

    Segment adjusted EBITDA

     

     

     

     

     

     

    Software and Analytics

     

    $

    272,683

     

     

    261,325

    Network Solutions

     

     

    222,474

     

     

    165,011

    Technology-Enabled Services

     

     

    34,033

     

     

    2,360

    Postage and Eliminations

     

     

    —

     

     

    —

    Total adjusted EBITDA

     

    $

    529,190

     

     

    428,696

    (1)

    Revenue for Postage and Eliminations includes postage revenue of $52.6 million for the three months ended September 30, 2021 and $50.0 million for the three months ended September 30, 2020. Revenue for Postage and Eliminations includes postage revenue of $103.8 million for the six months ended September 30, 2021 and $95.8 million for the six months ended September 30, 2020.

    (2)

    Amount reflects the impact to deferred revenue resulting from the McKesson exit which reduced revenue recognized during the three months ended September 30, 2021 and September 30, 2020.

     

     

    Reconciliation of Cash Provided by (Used in) Operating Activities to Free Cash Flow and Adjusted Free Cash Flow

    (unaudited and amounts in thousands)

     

     

     

     

     

     

     

     

     

    Six Months Ended September 30,

     

     

    2021

     

    2020

    Cash provided by (used in) operating activities (1)

     

    $

    261,351

     

    $

    296,557

    Capital expenditures

     

     

    (126,828)

     

     

    (126,432)

    Free cash flow

     

     

    134,523

     

     

    170,125

    Adjustments to free cash flow (2):

     

     

     

     

     

     

    Integration and related costs

     

     

    17,301

     

     

    17,894

    Strategic initiatives, duplicative and transition costs

     

     

    24,572

     

     

    8,845

    Severance costs

     

     

    12,023

     

     

    7,876

    Integration and strategic capital expenditures

     

     

    13,483

     

     

    5,938

    Adjusted free cash flow

     

    $

    201,902

     

    $

    210,678

    (1)

    Includes cash provided by pass-thru funds of $4.4 million for the six months ended September 30, 2021 and cash used by pass-thru funds of $1.4 million for the six months ended September 30, 2020.

    (2)

    All operating costs and integration and strategic capital expenditures are presented on an as-incurred basis.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005955/en/

    Get the next $CHNG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CHNG

    DatePrice TargetRatingAnalyst
    9/20/2022$26.00 → $27.75Overweight → Neutral
    Piper Sandler
    9/20/2022$27.75Buy → Neutral
    Citigroup
    9/7/2022$27.75Hold
    Truist
    4/1/2022$25.75Neutral
    Credit Suisse
    2/4/2022$25.75Neutral → Buy
    Citigroup
    More analyst ratings

    $CHNG
    Leadership Updates

    Live Leadership Updates

    See more
    • OptumInsight and Change Healthcare Combine to Advance a More Modern, Information and Technology-Enabled Health Care Platform

      EDEN PRAIRIE, Minn. & NASHVILLE, Tenn.--(BUSINESS WIRE)--Optum, a diversified health services company and part of UnitedHealth Group (NYSE: UNH), and Change Healthcare (NASDAQ: CHNG), a health care technology leader, have agreed to combine. Change Healthcare will join with OptumInsight to provide software and data analytics, technology-enabled services and research, advisory and revenue cycle management offerings to help make health care work better for everyone. This combination unites two technology and service companies focused on serving health care. Their combined capabilities will more effectively connect and simplify core clinical, administrative and payment processes - resu

      1/6/21 6:00:00 AM ET
      $UNH
      $CHNG
      Medical Specialities
      Health Care
      Managed Health Care

    $CHNG
    SEC Filings

    See more
    • SEC Form 15-12G filed by Change Healthcare Inc.

      15-12G - Change Healthcare Inc. (0001756497) (Filer)

      10/13/22 4:31:29 PM ET
      $CHNG
      Managed Health Care
      Health Care
    • SEC Form S-8 POS filed by Change Healthcare Inc.

      S-8 POS - Change Healthcare Inc. (0001756497) (Filer)

      10/3/22 4:16:35 PM ET
      $CHNG
      Managed Health Care
      Health Care
    • SEC Form 25-NSE filed by Change Healthcare Inc.

      25-NSE - Change Healthcare Inc. (0001756497) (Subject)

      10/3/22 9:26:21 AM ET
      $CHNG
      Managed Health Care
      Health Care

    $CHNG
    Financials

    Live finance-specific insights

    See more
    • AM Best Comments on Credit Ratings of UnitedHealth Group Incorporated and Its Subsidiaries Following Completion of Change Healthcare Inc. Acquisition

      AM Best has commented that the Credit Ratings (ratings) of UnitedHealth Group Incorporated (UnitedHealth Group) (Minnetonka, MN) (NYSE:UNH) and its insurance subsidiaries remain unchanged following its completed acquisition of Change Healthcare Inc. (Change Healthcare) (Nashville, TN) (NASDAQ:CHNG), a leading health care technology company. The outlooks of these Credit Ratings (ratings) remain stable. The close of this transaction had been delayed following the antitrust suit from the U.S. Department of Justice; however, the U.S. federal judge cleared the way for the transaction to be completed late in September. The close of the transaction was announced on Oct. 3, 2022. The transaction i

      10/4/22 11:34:00 AM ET
      $CHNG
      $UNH
      Managed Health Care
      Health Care
      Medical Specialities
    • District Court Denies Request to Enjoin Acquisition of Change Healthcare Inc. by UnitedHealth Group Incorporated: Change Healthcare Inc: Announces Special Cash Dividend

        Yesterday, the U.S. District Court for the District of Columbia issued an opinion and final appealable order denying the request made by the U.S. Department of Justice and the States of New York and Minnesota for the Court to enjoin UnitedHealth Group Incorporated (NYSE:UNH) ("UnitedHealth Group") from acquiring Change Healthcare Inc. (NASDAQ:CHNG) (the "Company" or "Change Healthcare") pursuant to the proposed merger (the "Merger") between the Company and a wholly owned subsidiary of UnitedHealth Group, which will result in the combination of the Company and Optum Insight, a part of UnitedHealth Group. The opinion and final appealable order also require UnitedHealth Group and the Compan

      9/20/22 5:15:00 PM ET
      $CHNG
      $UNH
      Managed Health Care
      Health Care
      Medical Specialities
    • Change Healthcare Inc. Reports First Quarter Fiscal 2023 Financial Results

      Revenue growth driven by continued momentum in core business and investment in expanded capabilities Total revenue of $884M, including solutions revenue of $831M; solutions revenue growth of 1.8% driven by increased volume and new sales Change Healthcare Inc. (NASDAQ:CHNG) (the "Company" or "Change Healthcare"), a leading healthcare technology company, today reported financial results for the first quarter of fiscal year 2023 ended June 30, 2022. "Our first quarter growth, despite headwinds from lower COVID-related activities and customer attrition related to the extended merger process, demonstrates the underlying momentum in the business," said Neil de Crescenzo, president and chief

      8/3/22 4:15:00 PM ET
      $CHNG
      Managed Health Care
      Health Care

    $CHNG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $CHNG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Change Healthcare downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Change Healthcare from Overweight to Neutral and set a new price target of $27.75 from $26.00 previously

      9/20/22 7:30:37 AM ET
      $CHNG
      Managed Health Care
      Health Care
    • Change Healthcare downgraded by Citigroup with a new price target

      Citigroup downgraded Change Healthcare from Buy to Neutral and set a new price target of $27.75

      9/20/22 7:30:06 AM ET
      $CHNG
      Managed Health Care
      Health Care
    • Truist initiated coverage on Change Healthcare with a new price target

      Truist initiated coverage of Change Healthcare with a rating of Hold and set a new price target of $27.75

      9/7/22 7:16:06 AM ET
      $CHNG
      Managed Health Care
      Health Care
    • SEC Form SC 13G/A filed by Change Healthcare Inc. (Amendment)

      SC 13G/A - Change Healthcare Inc. (0001756497) (Subject)

      2/2/23 5:01:01 PM ET
      $CHNG
      Managed Health Care
      Health Care
    • SEC Form SC 13D filed by Change Healthcare Inc.

      SC 13D - Change Healthcare Inc. (0001756497) (Subject)

      10/7/22 3:12:53 PM ET
      $CHNG
      Managed Health Care
      Health Care
    • SEC Form SC 13G/A filed by Change Healthcare Inc. (Amendment)

      SC 13G/A - Change Healthcare Inc. (0001756497) (Subject)

      2/14/22 11:59:59 AM ET
      $CHNG
      Managed Health Care
      Health Care

    $CHNG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Rareshide Paul was granted 9,177 shares and returned $302,073 worth of shares to the company (49,968 units at $6.05), closing all direct ownership in the company

      4 - Change Healthcare Inc. (0001756497) (Issuer)

      10/5/22 4:32:34 PM ET
      $CHNG
      Managed Health Care
      Health Care
    • SEC Form 4: Domenici Nella returned 29,280 shares to the company, closing all direct ownership in the company

      4 - Change Healthcare Inc. (0001756497) (Issuer)

      10/5/22 4:32:12 PM ET
      $CHNG
      Managed Health Care
      Health Care
    • SEC Form 4: De Crescenzo Neil E. returned $15,274,411 worth of shares to the company (1,557,392 units at $9.81) and was granted 220,264 shares, closing all direct ownership in the company

      4 - Change Healthcare Inc. (0001756497) (Issuer)

      10/5/22 4:31:54 PM ET
      $CHNG
      Managed Health Care
      Health Care

    $CHNG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AM Best Comments on Credit Ratings of UnitedHealth Group Incorporated and Its Subsidiaries Following Completion of Change Healthcare Inc. Acquisition

      AM Best has commented that the Credit Ratings (ratings) of UnitedHealth Group Incorporated (UnitedHealth Group) (Minnetonka, MN) (NYSE:UNH) and its insurance subsidiaries remain unchanged following its completed acquisition of Change Healthcare Inc. (Change Healthcare) (Nashville, TN) (NASDAQ:CHNG), a leading health care technology company. The outlooks of these Credit Ratings (ratings) remain stable. The close of this transaction had been delayed following the antitrust suit from the U.S. Department of Justice; however, the U.S. federal judge cleared the way for the transaction to be completed late in September. The close of the transaction was announced on Oct. 3, 2022. The transaction i

      10/4/22 11:34:00 AM ET
      $CHNG
      $UNH
      Managed Health Care
      Health Care
      Medical Specialities
    • District Court Denies Request to Enjoin Acquisition of Change Healthcare Inc. by UnitedHealth Group Incorporated: Change Healthcare Inc: Announces Special Cash Dividend

        Yesterday, the U.S. District Court for the District of Columbia issued an opinion and final appealable order denying the request made by the U.S. Department of Justice and the States of New York and Minnesota for the Court to enjoin UnitedHealth Group Incorporated (NYSE:UNH) ("UnitedHealth Group") from acquiring Change Healthcare Inc. (NASDAQ:CHNG) (the "Company" or "Change Healthcare") pursuant to the proposed merger (the "Merger") between the Company and a wholly owned subsidiary of UnitedHealth Group, which will result in the combination of the Company and Optum Insight, a part of UnitedHealth Group. The opinion and final appealable order also require UnitedHealth Group and the Compan

      9/20/22 5:15:00 PM ET
      $CHNG
      $UNH
      Managed Health Care
      Health Care
      Medical Specialities
    • Change Healthcare Inc. Reports First Quarter Fiscal 2023 Financial Results

      Revenue growth driven by continued momentum in core business and investment in expanded capabilities Total revenue of $884M, including solutions revenue of $831M; solutions revenue growth of 1.8% driven by increased volume and new sales Change Healthcare Inc. (NASDAQ:CHNG) (the "Company" or "Change Healthcare"), a leading healthcare technology company, today reported financial results for the first quarter of fiscal year 2023 ended June 30, 2022. "Our first quarter growth, despite headwinds from lower COVID-related activities and customer attrition related to the extended merger process, demonstrates the underlying momentum in the business," said Neil de Crescenzo, president and chief

      8/3/22 4:15:00 PM ET
      $CHNG
      Managed Health Care
      Health Care